423 related articles for article (PubMed ID: 32303620)
21. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
22. The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer.
Meng S; Li M; Qin L; Lv J; Wu D; Zheng D; Jia H; Chen D; Wu Q; Long Y; Tang Z; Tang Y; Yang L; Yao Y; Luo X; Li P
Int Immunopharmacol; 2023 Aug; 121():110402. PubMed ID: 37301125
[TBL] [Abstract][Full Text] [Related]
23. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
[TBL] [Abstract][Full Text] [Related]
24. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
25. Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers.
Ba H; Dai Z; Zhang Z; Zhang P; Yin B; Wang J; Li Z; Zhou X
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720496
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer.
Li Y; Xiao F; Zhang A; Zhang D; Nie W; Xu T; Han B; Seth P; Wang H; Yang Y; Wang L
Cell Immunol; 2020 Feb; 348():104041. PubMed ID: 31983398
[TBL] [Abstract][Full Text] [Related]
27. Developing ROR1 Targeting CAR-T Cells against Solid Tumors in Preclinical Studies.
Lee BK; Wan Y; Chin ZL; Deng L; Deng M; Leung TM; Hua J; Zhang H
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892876
[TBL] [Abstract][Full Text] [Related]
28. Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.
Kloss CC; Lee J; Zhang A; Chen F; Melenhorst JJ; Lacey SF; Maus MV; Fraietta JA; Zhao Y; June CH
Mol Ther; 2018 Jul; 26(7):1855-1866. PubMed ID: 29807781
[TBL] [Abstract][Full Text] [Related]
29. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.
Wei H; Wang Z; Kuang Y; Wu Z; Zhao S; Zhang Z; Li H; Zheng M; Zhang N; Long C; Guo W; Nie C; Yang H; Tong A
Front Immunol; 2020; 11():573823. PubMed ID: 33072116
[TBL] [Abstract][Full Text] [Related]
30. SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors.
Liang S; Zheng R; Zuo B; Li J; Wang Y; Han Y; Dong H; Zhao X; Zhang Y; Wang P; Meng R; Jia L; Yang A; Yan B
Cell Mol Immunol; 2024 Mar; 21(3):213-226. PubMed ID: 38177245
[TBL] [Abstract][Full Text] [Related]
31. miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer.
Tao J; Zhi X; Zhang X; Fu M; Huang H; Fan Y; Guan W; Zou C
J Exp Clin Cancer Res; 2015 Nov; 34():139. PubMed ID: 26576539
[TBL] [Abstract][Full Text] [Related]
32. Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β.
Alabanza LM; Xiong Y; Vu B; Webster B; Wu D; Hu P; Zhu Z; Dropulic B; Dash P; Schneider D
Front Immunol; 2022; 13():832645. PubMed ID: 35222421
[TBL] [Abstract][Full Text] [Related]
33. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors.
Tang N; Cheng C; Zhang X; Qiao M; Li N; Mu W; Wei XF; Han W; Wang H
JCI Insight; 2020 Feb; 5(4):. PubMed ID: 31999649
[TBL] [Abstract][Full Text] [Related]
34. EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC.
Liu Y; Zhou Y; Huang KH; Li Y; Fang X; An L; Wang F; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
Aging (Albany NY); 2019 Dec; 11(23):11054-11072. PubMed ID: 31804974
[TBL] [Abstract][Full Text] [Related]
35. Galunisertib enhances chimeric antigen receptor-modified T cell function.
Wang Z; Liu Q; Risu N; Fu J; Zou Y; Tang J; Li L; Liu H; Zhou G; Zhu X
Eur J Histochem; 2020 Jun; 64(s2):. PubMed ID: 32705856
[TBL] [Abstract][Full Text] [Related]
36. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
[TBL] [Abstract][Full Text] [Related]
37. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
[TBL] [Abstract][Full Text] [Related]
38. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
Han Y; Xie W; Song DG; Powell DJ
J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
[TBL] [Abstract][Full Text] [Related]
39. TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.
Byrd TT; Fousek K; Pignata A; Szot C; Samaha H; Seaman S; Dobrolecki L; Salsman VS; Oo HZ; Bielamowicz K; Landi D; Rainusso N; Hicks J; Powell S; Baker ML; Wels WS; Koch J; Sorensen PH; Deneen B; Ellis MJ; Lewis MT; Hegde M; Fletcher BS; St Croix B; Ahmed N
Cancer Res; 2018 Jan; 78(2):489-500. PubMed ID: 29183891
[TBL] [Abstract][Full Text] [Related]
40. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.
Bajgain P; Tawinwung S; D'Elia L; Sukumaran S; Watanabe N; Hoyos V; Lulla P; Brenner MK; Leen AM; Vera JF
J Immunother Cancer; 2018 May; 6(1):34. PubMed ID: 29747685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
